Somatostatin (SRIF) analogs have been employed in medical therapy of non-functioning pituitary adenomas (NFA), with contrasting results. Previous evidence showed that SRIF
Introduction
Increased expression of vascular endothelial growth factor (VEGF), a specific mitogen for endothelial cell, has been demonstrated in several human neoplastic tissues (Ferrara 2001) , which is associated with blood vessel density, tumor growth, metastatic spread, disease progression, and poor prognosis (Itakura et al. 1997 , Seo et al. 2000 . Several studies have shown that VEGF is expressed in the pituitary gland and pituitary adenomas, where VEGF expression correlates with increased proliferation (Vidal et al. 2000 , Yamada & Takada 2003 . Moreover, elevated plasma VEGF levels have been demonstrated in patients harboring pituitary tumors (Komorowski et al. 2000) . In addition, increased concentrations of VEGF and of VEGF receptor 1 (VEGF-R1) were found in non-functioning pituitary adenomas (NFA) when compared with normal pituitaries (McCabe et al. 2002) , suggesting that VEGF and VEGF-R1 expression may be related to pituitary tumor growth and vascularization.
Previous evidence has shown that somatostatin (SRIF) and its analogs might exert antiproliferative effects on pituitary adenomas, by interacting with one or more of its five transmembrane G-protein-coupled receptors (SSTR1-5; Zatelli et al. 2006b ). In addition, overexpression of SSTR2 in human pancreatic cancer cells markedly reduced microvessel density and VEGF expression (Carrere et al. 2005 ), suggesting that SSTR2-induced antiproliferative effects might be mediated by a reduction in VEGF secretion and action in a paracrine fashion. Recently, a new universal SRIF analog with binding properties similar to native SRIF has been developed. The new compound, pasireotide, previously known as SOM230, has high affinity for and functional activity at SSTR1, 2, 3, and 5 , Schmid & Schoeffter 2004 . Pasireotide has been demonstrated to act as a powerful inhibitor of growth hormone (GH) secretion by normal somatotrophs in animal models and by somatotroph adenomas, both in vivo and in vitro (Hofland et al. 2005) . A recent study demonstrates that treatment with both octreotide and pasireotide are associated with the downregulation of pERK and upregulation of p27 in pituitary adenomas, possibly hampering cell cycle progression and inhibiting cell growth (Hubina et al. 2006) . Moreover, pasireotide has been reported to inhibit VEGF-stimulated endothelial cell proliferation (Adams et al. 2004 ). However, the mechanism by which such effect might take place in human NFA has never been investigated, so far.
We therefore investigated the effects of SRIF and of pasireotide on VEGF secretion and on cell viability in vitro in a group of 25 NFA.
Materials and methods

Materials
All reagents, if not otherwise specified, were purchased from Sigma-Aldrich (Milano, Italy) .
Human pituitary adenomas
Twenty-five clinically NFA (mean maximal diameter: 1.9G0.1 cm; mean volume: 3.8G1.9 cm 3 ) from 25 patients, aged 54.7G3.5 years (median 53 years), 10 males and 15 females, operated on for NFA were recruited for this study. Table 1 shows patients' characteristics and preoperative hormonal values. Patients had not been treated with SRIF analogs or with dopaminergic drugs prior to surgery. All patients underwent transsphenoidal surgery, and all specimens were examined for anterior pituitary hormones by immunohistochemistry. Among the 25 tumors, 3 were positive for follicle-stimulating hormone (FSH), 1 for lutenizing hormone (LH), 2 for prolactin (PRL), and 2 for both LH and FSH. No immunostaining for GH, TSH, and ACTH was detectable in these tumors and all anterior pituitary hormones were undetectable in the other 17 tumors. Therefore, these adenomas were histologically diagnosed as gonadotroph cell adenoma or null cell adenoma. Human total RNA from normal pituitary was used as a control for RT-PCRs (Analytical Biological Services Inc., Wilmington, Delaware, USA).
Tissue collection and primary culture
Tissue samples were collected in accordance with the guidelines of the local committee on human research. A fragment was immediately frozen in liquid nitrogen under ribonuclease (RNase)-free conditions at the time of surgery and stored at K80 8C until RNA isolation was performed. A portion of the fresh tissue was immediately processed for primary culture experiments as described previously (Zatelli et al. 2003a) . Cells were resuspended in high glucose DMEM with 10% FBS and antibiotics (EuroClone Ltd), seeded in 96-well culture plates (w2! 10 4 cells/well; w80-well/tumor) and incubated at 37 8C in a humidified atmosphere of 5% CO 2 and 95% air. Fibroblast contamination was excluded by treatment with cis-4-hydroxy-L-proline and morphological examination of the cultured cells (Danila et al. 2001) . After 24 h, the medium was changed to serum-free high glucose DMEM containing 0.2% BSA, 120 nM transferrin, 5 U/l insulin, 2 mM glutamine, and antibiotics. Cells were then treated with the indicated compounds for evaluation of VEGF secretion in conditioned medium, which was collected and stored at K20 8C for later measurement. Medium was then replaced with the indicated treatments for cell viability experiments. Informed consent of the patients was obtained for disclosing clinical investigation and performing the in vitro study.
Isolation of RNA and RT-PCR
In order to demonstrate the pituitary origin of the samples, RT-PCR analysis for a-subunit expression 
In vitro a VEGF was performed on each specimen, as reported previously (Zatelli et al. 2004) . Further expression analysis for VEGF, VEGF-R1, VEGF-R2, and SSTR1-SSTR5 was performed only in a-subunit-expressing tissues, as previously described (Zatelli et al. 2003b (Zatelli et al. , 2004 . Briefly, frozen tissues were disrupted and total RNA from the pulverized tumors was isolated with TRIzol reagent (Invitrogen), according to the manufacturer's protocol. To prevent DNA contamination, RNA was treated with RNase-free DNase (Promega). Using a first strand cDNA synthesis kit (SuperScript Preamplification System for First Strand cDNA Synthesis, Invitrogen), 1 mg total RNA was reversetranscribed with random hexamers according to the manufacturer's protocol. Reverse transcription (RT) reactions were performed by using the GeneAmp 9700 PCR System (Applera, Monza, Italy), as described previously (Zatelli et al. 2001 (Zatelli et al. , 2003a . PCR conditions and oligonucleotide primers for amplification are listed in Table 2 . Glyceraldehyde phosphate dehydrogenase (GAPDH) amplification was performed as control for RT reaction. PCR products were run on a 2% agarose gel, visualized by ethidium bromide staining, and analyzed with the Fluor-S Multi Imager (Bio-Rad). To confirm the correct identification of RT-PCR products, their specificity was verified, after gel purification by Quiaex II (Qiagen), by restriction enzyme digestion and direct sequencing (data not shown).
SSTR Quantitative PCR
Quantitative PCR (QPCR) for SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5 was performed as previously described (Zatelli et al. 2006a) , with primers and probes designed using Primer Express Software (Applied Biosystems, Monza, Italy). TaqMan probes (PE Applied Biosystems) labeled with a fluorescent dye (6-carboxy-fluorescein, FAM) and a quencher dye (6-carboxy-tetramethyl rhodamine, TAMRA) were used. For amplification of the house keeping gene the Pre-Developed TaqMan Assay Reagents for the Human 18S rRNA (20!) were used (PE Applied Biosystem). Serial dilutions of the single stranded SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5 sense oligonucleotide amplicons (from 10 9 to 10 2 molecules) were carried out in triplicate. The log copy numbers of unknown samples were calculated from the regression line according to the equation: log NZ(CtKq)/m, where Ct is the threshold cycle, q is the y-intercept, and m is the slope of the standard curve line. All QPCRs were performed, recorded, and analyzed using the ABI 7700 Prism Sequence Detection System Table 2 Primers and PCR conditions for a-subunit, SSTR 1-5, VEGF, VEGF-R1 and VEGF-R2 amplification in human NFA (PE Applied Biosystems). Slopes for all assays reported were K3.3G0.1.
All samples were carried out in triplicate (100 ng reverse-transcribed total RNA per well) and repeated at least twice. For each samples, one point of 18S rRNA was loaded to evaluate the retro-transcription efficiency in the same plate and PCR conditions. No Template Control and RT-controls were run in each experiment.
A cut-off of 3!10 3 mRNA copies/mg total RNA was established as the threshold for Real Time PCR to exclude the detection of transcripts due to illegitimate transcription, as suggested previously (Chelly et al. 1989 , Korbonits et al. 2001 .
SRIF and pasireotide
SRIF (Stilamin 250) was purchased from Serono Pharma (Roma, Italy). Functional responses were also investigated by using pasireotide (provided by Novartis Pharma, Basel, Switzerland), which affinities to the different SSTRs are listed in Table 3 , according to previously published evidence .
VEGF secretion
The effects of SRIF and pasireotide on VEGF secretion were analyzed by measuring human VEGF immunoreactivity with an ELISA kit (Pierce Biotechnology, Inc., Rockford, IL, USA) in the culture medium from primary cultured pituitary cells incubated for 8 h with or without 10 K8 M SRIF or pasireotide. The detection limit was 8 pg/ml, with intra-and inter-assay coefficients of variation of 8.9 and 7.3% respectively. Hormone assays were performed in duplicate after appropriate sample dilutions of conditioned medium from treated cells. Results were obtained by determining the mean value among eight replicates. Primary cultures were considered as 'responders' when a significant reduction O15% in VEGF secretion was recorded under treatment with SRIF.
Cell viability
The effect of SRIF and pasireotide on cell viability of pituitary adenomas in vitro was assessed by the CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay (Promega), as described previously (Zatelli et al. 2002) , after incubation for 48 h in medium without or with 10 K8 M SRIF or pasireotide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) is a colorimetric method for determining the number of viable cells, widely accepted and employed for cell viability assessment (Zatelli et al. 2003a) , as the recorded absorbance strongly correlates to the cell number, independently on whether they are proliferating or not. Treatments were renewed after the first 24 h of incubation. At the end of the incubation period, the plates were incubated for an additional 4 h at 37 8C in a humidified 5% CO 2 atmosphere with the staining solution. The absorbance at 490 nm was then recorded using an ELISA plate reader (EASIA Reader, Medgenix, Fleurus, Belgium). Results (absorbance at 490 nm) were obtained by determining the mean value of at least six experiments in eight replicates.
Statistical analysis
Results of hormone assays and cell viability experiments are expressed as the meanGS.E.M. A preliminary analysis was carried out to determine whether the datasets conformed to a normal distribution, and a computation of homogeneity of variance was performed using Bartlett's test. The results were compared within each group and between groups using ANOVA. If the F values were significant (P!0.05), Student's paired or unpaired t-test was used to evaluate individual differences between means.
Results
Somatostatin receptor mRNA expression
Twenty-five samples derived from patients operated on for NFA underwent RT-PCR analysis for a-sub. All samples expressed a-sub and therefore underwent evaluation of SSTR1-5, VEGF, VEGF-R1, and VEGF-R2 mRNA expression. All samples expressed VEGF and at least one VEGF receptor subtype (VEGF-R1 in 22, and VEGF-R2 in 23 samples). SSTR expression pattern was highly variable, as SSTR1 was expressed in 68% of the samples, SSTR2 in 88%, SSTR3 in 68%, SSTR4 in 64%, and SSTR5 in 36% (Table 4 ).
The absolute SSTRs mRNA levels were also investigated in the selected samples showing a meanGS.E.M. molecules/mg reverse-transcribed total RNA for SSTR1 mRNA of 3.1G0.1!10 5 , for SSTR2 mRNA of 1.1G0.3!10 9 , for SSTR3 mRNA of 8.0G 0.1!10 4 , for SSTR4 mRNA of 5.5G0.4!10 3 , and for SSTR5 mRNA of 6.6G0.2!10 6 ( Table 5) . No correlation was found between SSTR expression 
Effects of SRIF and pasireotide on VEGF secretion by NFA
In order to determine the effects of SRIF and of pasireotide on VEGF secretion by dispersed NFA cells, we assessed VEGF concentrations in conditioned medium from 25 NFA primary cultures, treated with SRIF or pasireotide. The basal VEGF level in the culture medium of 12!10 4 cells cultured for 12 h was 23.2G2.7 pg/ml. The primary cultures were then divided in two groups according to the extent of VEGF secretion inhibition recorded after treatment with SRIF. Cultures responding to SRIF with a VEGF reduction of 15% or greater versus untreated cells were considered as 'responders'. According to this criterion, 13 cultures were considered as 'responders' (group A) and 12 as 'non-responders' (group B). SSTR1 expression was found in 77% of NFA belonging to group A, and was four-fold greater than the levels found in the SSTR1-positive NFA (58%) belonging to group B (4.5G0.2!10 5 vs 1.1G0.2! 10 5 mRNA molecules/mg total RNA). Expression of SSTR2 in groups A and B was found in 92 and 85% of samples respectively, with similar mRNA levels (1.0G 0.3!10 9 vs 1.3G0.6!10 9 mRNA molecules/mg total RNA). On the other hand, SSTR3 was found in a similar proportion of NFA in the two groups (70 and 67% respectively), but mRNA expression levels were greater (wtwo-fold) in the 'responder' as compared with the 'non-responder' group (1.0G0.1!10 5 vs 5.7G0.6!10 4 mRNA molecules/mg total RNA). Expression of SSTR4 in group A and B was found in 54 and 75% of samples respectively, with similar mRNA levels (6.4G0.6!10 3 vs 4.8G0.5!10 3 mRNA molecules/mg total RNA). On the other hand, all NFA in group A lacked expression of SSTR5, which was expressed by 9 out of 12 NFA belonging to group B (6.6G0.4!10 6 mRNA molecules/mg total RNA). All samples that were negative for SSTR expression by qualitative PCR were confirmed by quantitative PCR, since their SSTR expression levels were below the threshold to exclude the detection of transcripts due to illegitimate transcription (!3!10 3 mRNA molecules/mg total RNA).
In group A, VEGF secretion was reduced by 24% (P!0.05) after treatment with SRIF and by 31% (P! 0.01 vs control; P!0.05 vs SRIF-treated cells) after treatment with the multiligand SSTR agonist pasireotide (Fig. 1) . In group B, treatment with SRIF or with pasireotide did not significantly influence VEGF secretion (Fig. 1) . In order to investigate whether SRIF and pasireotide influence VEGF secretion by interfering with the cAMP pathway, VEGF secretion was assessed in 5 'responder' NFA primary cultures treated for 8 h with or without 10 K6 M forskolin, and/ or 10 K8 M SRIF or pasireotide (Fig. 2) . This NFA subgroup (including samples #3, #6, #14, #16, #23) had a SSTR expression pattern and a mean number of SSTR1-5 mRNA molecules/mg total RNA similar to those of the hole group of 'responders' (Table 5) , indicating that these samples are representative of the responder NFA. Forskolin strongly induced VEGF secretion (C110%; P!0.01 vs control). As described previously, treatment with both SRIF and pasireotide significantly reduced VEGF secretion (K25 and K30%; P!0.05 and !0.01 respectively) and completely abrogated forskolin-induced VEGF secretion.
Effects of SRIF and of pasireotide on NFA cell viability
In order to determine the effects of SRIF and of pasireotide on cell viability of dispersed NFA cells, we assessed cell number in NFA primary cultures after a 48 h treatment with SRIF or pasireotide.
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Discussion
This study confirms and extends previous findings concerning the antisecretory and antiproliferative potential of SSTR agonists in human NFA in vitro, and provides further insights on the possible mechanisms triggered by SSTRs in pituitary adenomas.
We have previously shown that SSTRs differently influence hormone secretion of a selected group of NFA in vitro (Zatelli et al. 2004 ). In the present study, we subdivided the NFA samples into two groups, according to the in vitro response to SRIF in terms of VEGF secretion reduction. This selection criterion allowed us to identify two distinct groups, since the group of 'responders' completely lacked SSTR5 expression. Interestingly, in this group a greater number of samples expressed SSTR1, as compared with the 'non-responder' group. On the other hand, no Figure 1 Effects of SRIF and pasireotide on VEGF secretion by NFA. Pituitary cells were incubated in 96-well plates for 8 h in culture medium supplemented with either SRIF or pasireotide at 10 K8 M, and control cells were treated with vehicle solution. VEGF secretion by each primary culture was then measured by ELISA. As described in the Material and methods section, samples were divided according to VEGF secretion inhibition after treatment with SRIF in group A (responders, 13 samples, gray bars) and group B (non-responders, 12 samples, white bars). Data from NFA primary cultures were evaluated independently with eight replicates each, and were expressed as the meanGS.E.M. percent VEGF secretion inhibition versus untreated control cells. *P!0.05 and † P!0.01 vs untreated control cells; ‡ P!0.05 vs SRIF-treated cells.
Figure 2
Effects of forskolin on VEGF secretion by NFA. Five 'responder' pituitary primary cultures were incubated in 96-well plates for 8 h in culture medium supplemented with either SRIF or pasireotide at 10 K8 M, forskolin (Forsk) at 10 K6 M or both, and control cells were treated with vehicle solution. VEGF secretion by each primary culture was then measured by ELISA. Data from NFA primary cultures were evaluated independently with eight replicates each, and were expressed as the meanGS.E.M. percent VEGF secretion inhibition or induction vs untreated control cells. *P!0.05 and † P!0.01 vs untreated control cells.
Figure 3
Effects of SRIF and pasireotide on NFA cell viability. Pituitary cells were incubated in 96-well plates for 48 h in culture medium supplemented with either SRIF or pasireotide at 10 K 8 M, and control cells were treated with vehicle solution. Cell viability of each primary culture was measured as absorbance at 490 nm. As described in the Material and methods section, samples were divided according to VEGF secretion inhibition after treatment with SRIF in group A (responders, 13 samples, gray bars) and group B (non-responders, 12 samples, white bars). Data from NFA primary cultures were evaluated independently with eight replicates each, and were expressed as the meanGS.E.M. percent cell viability inhibition vs. untreated control cells. *P!0.05 vs untreated control cells. further difference was found between the two groups in terms of clinical characteristics or tumor volume. Our results show that the 'responder' group responds to SRIF and to pasireotide in terms of VEGF secretion inhibition, indicating that functionally active SSTRs are indeed expressed by these primary cultures. This evidence indicates that the signaling pathway downstream from SSTRs regulating the secretory processes is intact in these samples. This hypothesis is further supported by the evidence that SRIF and pasireotide can completely abrogate the effects of forskolin, a well known adenylate cyclase activator, on VEGF secretion. This evidence demonstrates that in NFA primary cultures SSTR agonists are capable of activating the respective receptors, which, in turn, can trigger intracellular pathways. In our hands, pasireotide was more effective than SRIF in reducing VEGF secretion in the 'responder' group. The greater potency of this compound might be due to high affinity binding to several SSTR subtypes , Lamberts et al. 2002 . However, pasireotide has a fiveand a four-fold lower affinity to SSTR1 and SSTR2 respectively, than SRIF. Therefore, the greater potency might be ascribed to the prolonged half-life of the compound and to the reduced induction of SSTR desensitization . Pasireotide has a greater affinity for SSTR5 as compared to SRIF, but the 'responder' group does not express such receptor. Moreover, in the 'responder' group, the reduction in VEGF secretion is mirrored by a nearly parallel reduction in cell viability induced by treatment with SRIF or pasireotide. These results suggest that, at least in part, the antiproliferative effects of SRIF analogs might be mediated by a reduced VEGF secretion. This hypothesis is further strengthened by the evidence that SRIF and pasireotide completely abrogated the promoting effects of VEGF on cell viability.
In the 'non-responder' group, SRIF and pasireotide did not influence both VEGF secretion and cell viability. This evidence might suggest that these NFA display functionally inactive SSTRs, or that the signaling pathways downstream from SSTRs are somehow disrupted. The lack of SSTR5 expression in all NFA samples belonging to the 'responder' group and the presence of this receptor in most of the 'nonresponder' group also suggests that SSTR5 might interact with the other SSTRs, hampering receptor activation, inhibiting intracellular signaling or counteracting the effects of other SSTRs activation. This latter hypothesis is in line with our previous data showing that a SSTR5-selective agonist promotes cell viability in a selected group of NFA expressing SSTR5 (Zatelli et al. 2004 ). These data would indicate a stimulatory role for SSTR5 in NFA cell proliferation, suggesting that the use of compounds selectively interacting with SSTR5 in NFA medical therapy might be counterproductive. In addition, this effect might account for the lack of volume reduction (Colao et al. 2000 , Andersen et al. 2001 or the increase in tumor volume (Gasperi et al. 1993 ) observed in NFA patients treated with octreotide or lanreotide, which mainly interacts with SSTR2 and SSTR5. However, this does not seem to be a general mechanism in pituitary adenomas, because previous evidence from somatotroph and corticotroph pituitary tumors suggests that the additional activation of SSTR5 might be responsible for the enhanced efficacy of SRIF analogs in reducing both secretion and cell proliferation (Shimon et al. 1997 , Hofland et al. 2005 . Moreover, some of the 'non-responder' NFA also lacked SSTR5 expression, suggesting that in these tumors pasireotide failure in reducing VEGF secretion should be ascribed to other mechanisms or to different SSTRs. It should be noted, indeed, that these NFA samples also lacked SSTR3 expression, which was nearly two-fold greater in 'responders' as compared with 'non-responders' NFA. It has been previously demonstrated that SSTR3 activation induces apoptosis through a p53dependent mechanism (Sharma et al. 1996) . We can therefore hypothesize that SRIF and pasireotide might exert their inhibitory effects also by interacting with SSTR3, which is more expressed in 'responder' tumors. Similarly, SSTR1 activation has been demonstrated to effectively reduce cell viability not only in NFA (Zatelli et al. 2004) , but also in GH/PRLsecreting pituitary adenomas (Zatelli et al. 2003a) . The data presented here are in line with an antiproliferative effect of SSTR1-interacting drugs in pituitary adenomas, since, nearly 80% of 'responder' NFA express SSTR1. It has been demonstrated that SSTR1 activation results in decreased secretory activity and reduced cell viability also in medullary thyroid carcinoma (Zatelli et al. 2006a,b) , suggesting that SSTR1 agonists may be effective on a wide range of endocrine cells. Indeed, almost all human tumors express SSTR1 mRNA (Patel 1997 ), suggesting that compounds also targeting SSTR1, such as pasireotide, might represent a good tool for the control of neoplastic growth. Moreover, an immunohistochemical study demonstrated that SSTR1 is one of the most expressed SSTR subtypes in NFA (Pawlikowski et al. 2003) . Therefore, stable SRIF analogs binding with high affinity to SSTR1, whether selectively or together with other SSTR subtypes, may indeed open a new frontier in the treatment of NFA. The SSTR2 subtype has been implicated in transducing the antiproliferative effects of SRIF in many animal and human models (Zatelli et al. 2001 , 2006a ,b, Guillermet-Guibert et al. 2005 . We previously reported that, in a selected group of NFA, SSTR2 selective activation was ineffective in influencing cell viability in vitro (Zatelli et al. 2004 ). In the present report both the 'responder' and the 'nonresponder' group equally expressed SSTR2, further supporting the hypothesis that the expression of multiple SSTR subtypes might profoundly influence the final effect of simultaneous receptor activation, as in the presence of a multireceptor ligand such as pasireotide. A similar mechanism might be supposed for SSTR3, which is equally expressed both in the 'responder' and the 'non-responder' groups, and has previously been demonstrated to promote apoptosis upon activation (Sharma et al. 1996) .
VEGF has been implicated in the angiogenetic processes in pituitary adenomas, even if the role of increased vascularity in pituitary tumors is still controversial. Some authors indeed report increased angiogenesis in pituitary adenomas (Weiner et al. 1995) , while others observe a reduced intratumoral vessel number (Turner et al. 2000) . VEGF mRNA expression has been demonstrated to be increased in NFA, where it associates with the expression of pituitary tumor transforming gene (PTTG). It has been demonstrated that PTTG transforms cells in vitro and is tumorigenic in vivo, being also capable of inducing VEGF expression (McCabe et al. 2002) . These data suggest that autocrine VEGF secretion might contribute to pituitary adenoma cell proliferation and/or transformation. Our data are in agreement with previous evidence showing that VEGF and its receptor, VEGF-R1, are widely expressed in NFA (McCabe et al. 2002) , also providing the basis of a possible autocrine loop. In addition, our results support the hypothesis that SRIF analogs might exert their antiproliferative effects by reducing VEGF secretion, consequently hampering VEGF effects. Indeed, treatment with SRIF and pasireotide completely abrogates the growth-promoting effects VEGF on NFA primary cultures. In addition, it has been previously reported that octreotide reduces blood vessel growth (Woltering et al. 1991) and inhibits proliferation of human umbilical vein endothelial cells (Danesi et al. 1997) . Our data also indicate that VEGF might promote pituitary proliferation both indirectly, by stimulating angiogenesis, and directly by promoting cell viability.
In conclusion, our results demonstrate that, in vitro, SRIF and pasireotide inhibit both VEGF secretion and cell viability in a subset of NFA. Our data are consistent with a greater effect for the multiligand SRIF analog pasireotide and suggest that the antiproliferative effects of SRIF agonists on NFA primary cultures might be mediated, at least in part, by VEGF secretion inhibition, with a consequent reduction in the autocrine growth factor loop.
